Background: HIV-exposed but uninfected (HEU) infants are at increased risk of impaired
early linear growth and cognitive development. We examined associations between …

Background WHO recommends daily co-trimoxazole for children born to HIV-infected
mothers from 6 weeks of age until breastfeeding cessation and exclusion of HIV infection …

Evidence-Based Neonatal Infections is expertly written by David Isaacs, an experienced
author renowned for his knowledge in both pediatric infections and evidence-based …

Background: The World Health Organization guidelines recommend cotrimoxazole
prophylactic treatment (CPT) for all HIV-exposed infants from age 6 weeks to the cessation …

Background Prophylactic cotrimoxazole is recommended for infants born to HIV-infected
mothers. However, cotrimoxazole may increase the risk of severe anemia or neutropenia …

Background: Given the potential of cotrimoxazole preventive therapy (CPT) to prevent
bacterial and malarial infections in HIV-exposed, uninfected (HEU) infants, it is important to …

Objective: In resource-limited settings without safe alternatives to breastfeeding, the WHO
recommends exclusive breastfeeding and antiretroviral (ARV) prophylaxis. Given the high …

Abstract The Side Effects of Drugs Annuals form a series of volumes in which the adverse
effects of drugs and adverse reactions to them are surveyed. The series supplements the …

Background In 2011, Tanzania adopted a policy for provision of daily co-trimoxazole
prophylaxis to HIV-infected pregnant women for prevention of malaria and other …

Background: The risk of in-utero and peripartum HIV acquisition in HIV-exposed infants born
prior to 37 weeks completed gestational age (preterm), is thought to be high when compared …